Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study
Open accessThe DOI matches its Crossref record; 60 of the 65 references it cites were found in a registry or an index; 6 of the 31 sources its claims cite were checked for support.
Abstract
Objectives: A reduced adrenal reserve-associated cortisol production relative to the enhanced needs of chronic inflammation (disproportion principle) has been observed in rheumatoid arthritis (RA). We examined the possible clinical value of diurnal cortisol measurements in active RA on treatment response prediction. Methods: Diurnal cortisol production (measured at: 08–12:00/18:00–22:00) was assessed by electrochemiluminescence immunoassay in 28 consecutive patients with moderately/highly active RA, as well as 3 and 6 months after treatment initiation or/escalation. Twenty-eight COVID-19 patients and 28 age-matched healthy individuals (HC) served as controls. Results: Saliva diurnal cortisol production in patients with RA was similar to that of HC, despite 12-fold higher serum C reactive protein (CRP) levels, and lower than COVID-19 patients (area under the curve: RA: 87.0±37.6 vs COVID-19: 146.7±14.3, p<0.001), having similarly high CRP. Moreover, a disturbed circadian cortisol rhythm at baseline was evident in 15 of 28 of patients with RA vs 4 of 28 and 20 of 28 of HC and COVID-19 patients, respectively. Treatment-induced minimal disease activity (MDA) at 6 months was achieved by 16 of 28 patients. Despite comparable demographics and clinical characteristics at baseline, non-MDA patients had lower baseline morning cortisol and higher adrenocorticotropic hormone (ACTH) levels compared with patients on MDA (cortisol: 10.9±4.0 vs 18.4±8.2 nmol/L, respectively, p=0.005 and ACTH: 4.8±3.3 vs 2.4±0.4 pmol/L, respectively, p=0.047). Baseline morning cortisol <13.9 nmol/L predicted non-MDA at 6 months (75% sensitivity, 92% specificity, p=0.006). Prospective measurements revealed that individualised diurnal cortisol production remained largely unchanged from baseline to 3 and 6 months. Conclusions: An impaired adrenal reserve is present in patients with RA. Further studies to confirm that assessment of diurnal cortisol production may be useful in guiding treatment decisions and/or predicting treatment response in RA are warranted. Trial registration number: NCT05671627.
Overview
CoChat Summary
TL;DR
In a 6-month real-life prospective cohort of 28 patients with active rheumatoid arthritis (RA), diurnal saliva cortisol production was comparable to healthy controls despite high inflammation and lower than in COVID-19 controls, suggesting impaired adrenal reserve. Baseline morning saliva cortisol <13.9 nmol/L predicted failure to achieve minimal disease activity (MDA) at 6 months with 75% sensitivity and 92% specificity.
Key findings
- Patients with active RA had saliva cortisol levels and time-integrated daily cortisol production comparable to healthy controls despite 12-fold higher CRP; night cortisol was higher in RA than controls (4.0±3.5 vs 1.9±0.8 nmol/L, p=0.005). RA patients had lower time-integrated daily cortisol production than COVID-19 patients (AUC 87±38 vs 147±75, p<0.001 in Results; abstract reports RA 87.0±37.6 vs COVID-19 146.7±14.3, p<0.001).
- A disturbed circadian cortisol rhythm was present in 15/28 RA patients vs 4/28 healthy controls and 20/28 COVID-19 patients (both p<0.01).
- At 6 months, 16/28 patients achieved MDA. Non-MDA patients had lower baseline morning saliva cortisol (10.9±4.0 vs 18.4±8.2 nmol/L, p=0.005) and higher ACTH (4.8±3.3 vs 2.4±0.4 pmol/L, p=0.047) than MDA patients. Baseline morning saliva cortisol <13.9 nmol/L predicted non-MDA (75% sensitivity, 92% specificity, p=0.006; adjusted OR 53.7, 95% CI 3.9 to 744). Of seven patients with both morning cortisol <13.9 nmol/L and disturbed rhythm, none achieved MDA.
- Individualised diurnal cortisol production remained largely unchanged from baseline to 3 and 6 months despite treatment-induced changes in disease activity and stress.
Methods
- Single-centre, 6-month prospective cohort: 30 consecutive patients with moderately/highly active RA (DAS28 >3.2) enrolled; 28 completed (24 female). Thirteen were newly diagnosed and initiated DMARDs; 15 required DMARD escalation. Controls were 28 age-matched healthy individuals and 28 age-matched COVID-19 patients from a previously published cohort.
- Saliva cortisol was measured at 08:00, 12:00, 18:00 and 22:00 by electrochemiluminescence immunoassay; plasma ACTH and serum CRP were measured at 08:00. Time-integrated daily cortisol production was calculated as AUC using the trapezoidal method. Assessments occurred at baseline, 3 and 6 months; MDA was defined as DAS28–ESR ≤2.85.
- Analyses included t-tests/Mann-Whitney U tests, Fisher’s exact test, ANOVA/Kruskal-Wallis with post hoc tests, repeated-measures tests, linear and logistic regression, and ROC curve analysis. No power calculation was performed in advance.
Limitations
- Stated by the authors: small sample size; inclusion of both early and established RA; explanatory analysis without power calculation; no unified treatment protocol and not all EULAR/ACR core set measures were recorded; stress and depression were not systematically assessed in control groups; no control group of patients with inactive RA at baseline.
- Evident from the text: single-centre real-life design with heterogeneous treatments; healthy and COVID-19 controls had limited sampling (baseline only for healthy controls and one time point for COVID-19 controls); small subgroup sizes limit precision of predictive estimates.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
3 Valid · 0 Not valid · 14 Not checked · 55 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Despite several attempts, including machine learning utilisation,42–44 no single established biomarker has been reported in a real-life setting.45”
§ Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study > Discussion
What the sources say
- Partly supportedcites [42] Guan, 2019, Machine learning to predict anti-tumor necrosis factor drug responses of rheumatoid arthritis patients by integrating clinical and genetic markers, Arthritis Rheumatol sourceExperimental — accuracy not yet measured
Guan et al. (2019) support the substance of 'no single established biomarker': the Background states that patient heterogeneity 'hinders identification of predictive biomarkers' and that demographic/clinical markers 'are not predictive enough to identify nonresponders by themselves', and the discussion notes that 'clinical information and genetic markers have relatively low predictive power themselves' and that cohort/geographic variation makes it 'challenging to apply these biomarkers to other cohorts'. However, the paper never frames this as a gap in a 'real-life setting' — its qualifier is cross-cohort transportability and anti-TNF response specifically, not RA treatment response generally — and it does not assert that no biomarker has been reported: the discussion says the opposite in part ('Previous studies also found several blood biomarkers that are informative of drug responses and are validated across different cohorts'). The 'real-life setting' element of the claim is therefore not attributable to this source. (LLM, conf=0.68)
- Partly supportedcites [43] Yoosuf, 2022, Early prediction of clinical response to anti-TNF treatment using multi-Omics and machine learning in rheumatoid arthritis, Rheumatology (Oxford) sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says that identifying predictive biomarkers is challenging and that the authors’ model requires independent validation before clinical use. This supports the narrower point that their proposed predictor is not established for clinical practice, but the paper does not state that no single biomarker has been reported in a real-life setting across rheumatoid arthritis treatment. (LLM, conf=0.78)
- Supportedcites [44] Bouget, 2022, Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts, RMD Open source
The Introduction states that several studies have sought biomarkers of response to TNF inhibitors in rheumatoid arthritis, but none has emerged as a reliable predictive factor. Its discussion of the need for markers in clinical practice supports the citing sentence’s real-life framing. (LLM, conf=0.88)
- Partly supportedcites [45] Wientjes, 2022, Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review, RMD Open sourceExperimental — accuracy not yet measured
The Discussion concludes that no single laboratory biomarker for predicting response to TNF inhibitors in rheumatoid arthritis currently has value for clinical practice. That supports the real-life-setting point, but the cited review is limited to TNF-inhibitor treatment and does not establish the claim for rheumatoid arthritis treatments generally. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similarly, individualised serial measurements of saliva cortisol during the day did not change significantly from baseline to 3 and 6 months.”
§ Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study > Results > Individualised diurnal production of cortisol is comparable overtime and not associated with treatment response
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Night cortisol levels, however, were higher in patients with RA than controls (4.0±3.5 vs 1.9±0.8 nmol/L, respectively, p=0.005) (figure 1A).”
§ Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study > Results > Impaired adrenal reserve in patients with active RA
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Prospective measurements revealed that individualised diurnal cortisol production remained largely unchanged from baseline to 3 and 6 months.”
§ Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline morning cortisol <13.9 nmol/L predicted non-MDA at 6 months (75% sensitivity, 92% specificity, p=0.006).”
- Also stated in: § WHAT THIS STUDY ADDS · plain
“In the current absence of relevant biomarkers, we found that low baseline saliva cortisol morning levels (<13.9 nmol/L) can predict with 75% sensitivity and 92% specificity an inadequate clinical response following 6-month treatment in a real-life setting.”
§ Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study > Abstract > Results
plainstates an associationn = 28- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § WHAT THIS STUDY ADDS · plain
39 more claims
Create a free account to see all 72 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 14
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic inflammation and persistent stress disrupt the physiological rhythm and feedback control of cortisol within the HPA axis [70], which is tightly coupled to circadian regulation.”
From Interorgan Communications in Skeletal Pathophysiology: From Molecular Pathways to Multidisciplinary Therapies (2026) · cites this paper as [70]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study > Results > Diurnal production of cortisol in patients with active RA at baseline predicts treatment response at 6 months
“| Moderately and severely depressed patients, n | 8/12 | 6/12 | 0.252 |”
§ Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study > Results > Diurnal production of cortisol in patients with active RA at baseline predicts treatment response at 6 months
“Patients onMDA at 6 months(n=16)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study > Abstract > Results
“RA: 87.0±37.6 vs COVID-19: 146.7±14.3, p<0.001”
§ Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study > Results > Impaired adrenal reserve in patients with active RA
“AUC: 87±38 vs 147±75, respectively, p<0.001, figure 1B”
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“In addition to clinical examination and DAS28 assessments, patients were asked to complete the Perceived Stress Scale Questionnaire-14 27 and the Hamilton Rating Scale Questionnaire for depression, 28 both validated for the Greek population, 29–31 at baseline, 3 and 6 months.”
A Global Measure of Perceived Stress
Cohen, S., Kamarck, T., & Mermelstein, R. (1983) · Journal of Health and Social Behavior · doi:10.2307/2136404 · Cited by 32,807 · cited 1×
“In addition to clinical examination and DAS28 assessments, patients were asked to complete the Perceived Stress Scale Questionnaire-14 27 and the Hamilton Rating Scale Questionnaire for depression, 28 both validated for the Greek population, 29–31 at baseline, 3 and 6 months.”
Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27584 · Cited by 9,619
Pruessner, J. C., Kirschbaum, C., Meinlschmid, G., & Hellhammer, D. H. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00108-7 · Cited by 3,638 · cited 1×
“34 Due to integration of diurnal cortisol measurements, AUC is expressed as a numerical value without any associated units.”
MethodSmolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216655 · Cited by 2,710 · cited 2×
“25 The Rheumatoid arthritis Rheumatoid arthritis Rheumatoid arthritis treating physicians were blinded to the baseline cortisol values.”
Design and analysis of pilot studies: recommendations for good practice
Lancaster, G. A., Dodd, S., & Williamson, P. R. (2004) · Journal of Evaluation in Clinical Practice · doi:10.1111/j..2002.384.doc.x · Cited by 2,572
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Perkins, N. J., & Schisterman, E. F. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj063 · Cited by 1,759 · cited 1×
“We used the point closest to (0.1) corner in the ROC curve 33 to define the optimal cut-off point value.”
InfluentialSalivary Cortisol in Psychobiological Research: An Overview
Kirschbaum, C., & Hellhammer, D. H. (2008) · Neuropsychobiology · doi:10.1159/000118611 · Cited by 1,532 · cited 2×
“15 During acute stress 16–18 or acute infection, 19 20 the rhythm is disturbed and the afternoon and/or midnight cortisol levels do not drop.”
Diurnal Cortisol Rhythm as a Predictor of Breast Cancer Survival
Sephton, S. E. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.12.994 · Cited by 1,082 · cited 1×
“15 During acute stress 16–18 or acute infection, 19 20 the rhythm is disturbed and the afternoon and/or midnight cortisol levels do not drop.”
Research works printed but not linked: 1
- 10.1136/ard-2022-223356 · doi:10.1136/ard-2022-223356 · Paper page
Cited by
Circadian and ultradian rhythms: Clinical implications
Lightman, S. L., & Conway-Campbell, B. L. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13795 · Cited by 35
Bournia, V.-K., Fragoulis, G., Mitrou, P., Tsolakidis, A., Mathioudakis, K., Vassilopoulos, D., Tektonidou, M. G., Paraskevis, D. N., & Sfikakis, P. P. (2024) · Rheumatology International · doi:10.1007/s00296-024-05733-y · Cited by 23
Self-citationDara, A., Vlachogiannis, N. I., Fragoulis, G., Tektonidou, M. G., & Sfikakis, P. P. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103914 · Cited by 9
Self-citationVlachogiannis, N. I., Verrou, K., Yavropoulou, M. P., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14298 · Cited by 4
“16 This inadequate response is observed also in treatment-naïve patients, suggesting an intrinsic defect of the HPA axis or even of the entire stress system, in RA, failing to be properly stimulated by inflammation, which under physiological conditions is a strong stimulus.”
Self-citationPain mechanism and management strategy of rheumatoid arthritis
Wang, D., Li, T., Wang, W. Y., Ruan, Y., Cai, J., & Yan, X. (2025) · Frontiers in Pain Research · doi:10.3389/fpain.2025.1693399 · Cited by 7
Metadata
- Authors
- Yavropoulou, M. P., Filippa, M. G., Vlachogiannis, N. I., Fragoulis, G. E., Laskari, K., Mantzou, A., Panopoulos, S., Fanouriakis, A., Bournia, V.-K., Evangelatos, G., Papapanagiotou, A., Tektonidou, M. G., Chrousos, G. P., & Sfikakis, P. P.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Department of Biological Chemistry, National and Kapodistrian University of Athens, Athens, Greece
- Corresponding author
- Sfikakis, Petros P
- ORCID
- Venue
- RMD Open
- Publisher
- BMJ
- Published
- 2024-01
- Volume
- 10
- Issue
- 1
- Pages
- e003575
- ISSN
- 2056-5933 (ISSN-L)
- PMC
- PMC10806498
- OpenAlex
- W4390956188
- Cited by
- 13
- References
- 65
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 4
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- RMD Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- rheumatoid arthritis, diurnal cortisol rhythm, treatment response prediction, minimal disease activity, ACTH, adrenal reserve, C-reactive protein, COVID-19 pandemic, salivary cortisol, disease activity monitoring
- MeSH terms
- COVID-19, Adrenocorticotropic Hormone, Arthritis, Rheumatoid, Humans, Hydrocortisone, Prospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study. https://app.cochat.ai/papers/10.1136/rmdopen-2023-003575
- The paper
- Yavropoulou, M. P., Filippa, M. G., Vlachogiannis, N. I., Fragoulis, G. E., Laskari, K., Mantzou, A., Panopoulos, S., Fanouriakis, A., Bournia, V.-K., Evangelatos, G., Papapanagiotou, A., Tektonidou, M. G., Chrousos, G. P., & Sfikakis, P. P. (2024). Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study. RMD Open. https://doi.org/10.1136/rmdopen-2023-003575
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.